Treatment of fibroids with hysteroscopic morcellation has pros and cons. For in-office treatment, the advantages and disadvantages are described here.
Though resection is still the most popular method of removing fibroids, the use of hysteroscopic morcellation has been on the rise since the first hysteroscopic morcellator became available in the United States in 2005.
Advantages of Morcellation
Morcellators use a blade and suction tube to simultaneously cut and remove tissue, which improves visibility and reduces the risk of perforations and gas embolus that are more likely with multiple equipment insertions.1 And because no energy is used in the uterine cavity, there is no risk of thermal injury.
Shorter operating time and ease of use are also among the principle advantages of the intra-uterine morcellator. 2,3 At an industry-sponsored breakfast at the 41st Global Congress of the American Association of Gynecologic Laparoscopists, AAGL’s past president Richard Gimpelson, MD, said, “If you can use an electric toothbrush, you can use [a] morcellator, that’s about how easy it is.”
Disadvantages of Morcellation
Morcellators cannot cauterize blood vessels and have limited utility in cases of Type II myomas.
For physicians wanting to use a hysteroscopic morcellator to perform in-office procedures, cost of the device and insurance reimbursement can be issues. Although the small size of the device makes it ideal for office procedures, the current system offers the same reimbursement rate for in-office and hospital or surgical-center procedures, which could make it cost-prohibitive for private practices.
Available Hysteroscopic Morcellation Systems
Currently, two morcellation systems are available in the United States: the TRUCLEAR™ Hysteroscopic Morcellator and the MyoSure® Tissue Removal System.
TRUCLEAR™ was the first to market in 2005, and the company released TRUCLEAR™ 5.0 in 2011. With an outer diameter 5 mm and a 2.9 mm morcellator, the TRUCLEAR™ 5.0 is presently the smallest morcellator on the market.
MyoSure® was first approved in 2009. Its system uses a 2mm morcellator and has an outer dimension of 6.25 mm.
1. Munro MG. Complications of hysteroscopic and uterine resectoscopic surgery. Obstet Gynecol Clin N Am.2010;37(3):399–425.
2. van Dongen H, Emanuel MH, Wolterbeek R, et al. Hysteroscopic morcellator for removal of intrauterine polyps and myomas: a randomized controlled pilot study among residents in training. J Minim Invasive Gynecol 2008; 15:466.
3. Emanuel MH, Wamsteker K. The Intra Uterine Morcellator: a new hysteroscopic operating technique to remove intrauterine polyps and myomas. J Minim Invasive Gynecol 2005; 12:62.
Advancing obstetric and gynecologic surgery through robotic innovation
April 30th 2024Explore how robotic surgery revolutionizes obstetric and gynecologic procedures, offering enhanced precision, reduced complications, and improved patient outcomes, while also examining challenges and future prospects in the field.
Read More
Unlocking placenta accreta spectrum with single-cell gene targets
April 18th 2024Discover how cutting-edge single-cell RNA sequencing unveils molecular insights into placenta accreta spectrum disorders, potentially revolutionizing diagnostics and treatments for this life-threatening pregnancy complication.
Read More
Excessive gonadotropins in IVF: Effects on mosaicism and live birth
April 12th 2024A recent study revealed a correlation between high doses and prolonged duration of exogenous gonadotropin use during in vitro fertilization and increased embryonic mosaicism alongside diminished live birth rates, prompting reconsideration of dosage and duration protocols.
Read More
Maternal history linked to uterine fibroid risk in Black women
April 11th 2024Delve into the findings of a recent study revealing the heightened risk of developing uterine fibroids among Black women with a maternal history of the condition, shedding light on crucial implications for patient care and advocacy.
Read More